Synaptogenix to Present at Sachs 5th Annual Neuroscience Innovation Forum
Synaptogenix (Nasdaq: SNPX) announced that Dr. Daniel Alkon will present on "Regenerative Therapeutics" at the Sachs Neuroscience Innovation Forum on March 22, 2022, at 8 am ET. The company reported promising results from its Phase 2 clinical trial of Bryostatin for advanced Alzheimer's patients, showing significant improvements in cognitive scores. The ongoing NIH-supported Phase 2B trial will further investigate Bryostatin’s effects. Synaptogenix is also planning trials for Fragile X syndrome and multiple sclerosis. Presentation details are available online and via social media.
- None.
- None.
NEW YORK, March 22, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, announced today that Dr. Daniel Alkon, the Company's President and Chief Scientific Officer, will present a "Spotlight Showcase" of Synaptogenix under the title "Regenerative Therapeutics" on Tuesday, March 22nd at 8am ET.
"Recently reported consolidated results of Synaptogenix Phase 2 clinical trial patients showed significant, persistent improvement of the cognitive psychometric Severe Impairment Battery (SIB) scores, over baseline, in a placebo-controlled publication on Bryostatin for advanced AD patients (Thompson, Tuchman, and Alkon, Journal Alzheimer's disease). We believe the persistence of the cognitive benefits for these patients is consistent with the 'rewiring' restoration of synapses demonstrated in extensive pre-clinical studies. This latest data offers encouragement for our ongoing NIH-supported, 6-month Phase 2B trial with AD patients. Clinical trials for other indications such as Fragile X syndrome and multiple sclerosis are also planned," stated Dr. Alkon.
The Company's presentation will be available on demand during the conference to registered participants through Sachs Forum website. It will also be accessible via social media one week after the meeting.
About Synaptogenix, Inc.
Synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases. Synaptogenix has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease. Preclinical studies have also demonstrated Bryostatin's regenerative mechanisms of action for the rare disease, Fragile X syndrome, and for other neurodegenerative disorders such as multiple sclerosis, stroke, and traumatic brain injury. The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome. Bryostatin-1 has already undergone testing in more than 1,500 people in cancer studies, thus creating a large safety data base that will further inform clinical trial designs. Additional information about Synaptogenix, Inc. may be found on its website: www.synaptogen.com .
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. These forward-looking statements include statements regarding the Phase 2 clinical trial of Bryostatin-1 and further studies, and continued development of use of Bryostatin-1 for AD and other cognitive diseases. Such forward-looking statements are subject to risks and uncertainties and other influences, many of which the Company has no control over. There can be no assurance that the clinical program for Bryostatin-1 will be successful in demonstrating safety and/or efficacy, that we will not encounter problems or delays in clinical development, or that Bryostatin-1 will ever receive regulatory approval or be successfully commercialized. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Additional factors that may influence or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing, the significant length of time associated with drug development and related insufficient cash flows and resulting illiquidity, the Company's patent portfolio, the Company's inability to expand its business, significant government regulation of pharmaceuticals and the healthcare industry, lack of product diversification, availability of the Company's raw materials, existing or increased competition, stock volatility and illiquidity, and the Company's failure to implement its business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the Securities and Exchange Commission. The Company does not undertake to update these forward-looking statements.
Contact information:
Investors and Media
800-811-5591
ir@synaptogen.com
Robert Weinstein
Chief Financial Officer
Synaptogenix, Inc.
rweinstein@synaptogen.com
View original content:https://www.prnewswire.com/news-releases/synaptogenix-to-present-at-sachs-5th-annual-neuroscience-innovation-forum-301507616.html
SOURCE Synaptogenix, Inc.
FAQ
What did Synaptogenix announce on March 22, 2022?
What are the results of Synaptogenix's Phase 2 clinical trial?
What is Bryostatin being tested for?
Where can I watch the Synaptogenix presentation?
What is the significance of the Phase 2B trial for Synaptogenix?
